RYTELO Demand and Commercial Execution“We delivered another quarter of net revenue growth, expanding RYTELO’s reach to more eligible patients,” Semerjian said. Geron said RYTELO demand increased 5% in the second quarter compared with the first quarter, marking its third consecutive quarter of demand growth. Chief Financial Officer Michelle Robertson said the company expects consistent quarter-over-quarter revenue growth through the remainder of 2026. The company expects to provide an update on its European commercialization plans before the end of 2026. Semerjian said Rath’s appointment supports the company’s effort to identify strategic growth opportunities and build Geron into a leading hematology company.